Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice1

The role of NKT cells on antitumor activity of CpG oligodeoxynucleotides (ODNs) was evaluated by peritumoral injections of CpG-ODNs in s.c. melanoma-bearing mice of strains differing in the number of NKT cells (athymic nude mice, recombination-activating gene−/−/transgenic Vα14/Vβ8.2 mice that generate NKT cells; Jα281−/− mice and CD1−/− mice, which both have a strongly reduced number of NKT cells; and C57BL/6 wild-type mice). Tumor growth was significantly inhibited in strains enriched or depleted of NKT cells. The two murine strains having a reduced number of NKT cells differed significantly in the CpG-dependent tumor growth inhibition: in Jα281−/− mice this inhibition was superimposable to that observed in C57BL/6 mice, while in CD1−/− mice the inhibition was dramatic. The increased tumor inhibition in CD1−/− correlated with a significantly higher ratio of IFN-γ-IL-4 production in response to CpG as compared with C57BL/6 and Jα281−/− mice. Experiments in which preparations of APCs and lymphocytes of the three strains were mixed showed that in the presence of APCs not expressing CD1, the production of CpG-ODN-induced type 1 cytokines was higher. Phenotype analysis of IFN-γ- and IL-4-producing cells revealed that the differences between CD1−/− and C57BL/6 in the production of these two cytokines were mainly due to CD3+ T lymphocytes. These data point to a regulatory role for the CD1 molecule in antitumor activity induced by danger signals, independently of Vα14 NKT cells. The identification of a CD1-dependent suppressive subpopulation(s) might have important implications for the study of tolerance in the context of cancer, autoimmunity, and transplantation.

[1]  F. Sallusto,et al.  In Vivo Persistence of Expanded Clones Specific for Bacterial Antigens within the Human T Cell Receptor ce//~ CD4-8- Subset By Paolo Dellabona,* Giulia Casorati,* Brigitte Friedli, , 1993 .

[2]  B. Echtenacher,et al.  Antimetastatic effect of CpG DNA mediated by type I IFN. , 2001, Cancer research.

[3]  S. Snapper,et al.  Involvement of CD1 in Peripheral Deletion of T Lymphocytes Is Independent of NK T Cells1 , 2001, The Journal of Immunology.

[4]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[5]  M. Roncarolo,et al.  The role of different subsets of T regulatory cells in controlling autoimmunity. , 2000, Current opinion in immunology.

[6]  T. Ratliff,et al.  APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells1 , 2000, The Journal of Immunology.

[7]  S. Ullrich,et al.  Immune suppression and skin cancer development: regulation by NKT cells , 2000, Nature Immunology.

[8]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[9]  M. Smyth,et al.  NKT cells: facts, functions and fallacies. , 2000, Immunology today.

[10]  S. Ménard,et al.  Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. , 2000, Cancer research.

[11]  D. Schadendorf,et al.  Conference on cancer vaccines , 2000, Cancer Immunology, Immunotherapy.

[12]  L. Kaer,et al.  Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. , 2000, International immunology.

[13]  S. Sakaguchi Regulatory T cells , 2006, Springer Seminars in Immunopathology.

[14]  T. Chun,et al.  Comparative Contribution of CD1 on the Development of CD4+ and CD8+ T Cell Compartments1 , 2000, The Journal of Immunology.

[15]  H. Macdonald CD1d–Glycolipid Tetramers: A New Tool to Monitor Natural Killer T Cells in Health and Disease , 2000 .

[16]  H. Davis Use of CpG DNA for enhancing specific immune responses. , 2000, Current topics in microbiology and immunology.

[17]  A Radbruch,et al.  Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. , 2000, Immunity.

[18]  Lin Chen,et al.  Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. , 1999, Cancer research.

[19]  H. Macdonald,et al.  Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. , 1999, Journal of immunology.

[20]  A. Levin,et al.  Evaluation of the Renal Effects of an Antisense Phosphorothioate Oligodeoxynucleotide in Monkeys , 1999, Toxicologic pathology.

[21]  D. Mason,et al.  Peripheral Autoantigen Induces Regulatory T Cells that Prevent Autoimmunity , 1999, The Journal of experimental medicine.

[22]  M. Kronenberg,et al.  The Murine Nonclassical Class I Major Histocompatibility Complex–like CD1.1 Molecule Protects Target Cells from Lymphokine-activated Killer Cell Cytolysis , 1999, The Journal of experimental medicine.

[23]  H. Wagner,et al.  Bacterial CpG DNA activates immune cells to signal infectious danger. , 1999, Advances in immunology.

[24]  M. Brenner,et al.  Diverse TCRs recognize murine CD1. , 1999, Journal of immunology.

[25]  H. Macdonald,et al.  Rapid Death and Regeneration of NKT Cells in Anti-CD3ε- or IL-12-Treated Mice , 1998 .

[26]  J. Harty,et al.  CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. , 1998, Journal of immunology.

[27]  M. Alegre,et al.  Tissue distribution, regulation and intracellular localization of murine CD1 molecules. , 1998, Molecular immunology.

[28]  K. Heeg,et al.  CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. , 1998, Journal of immunology.

[29]  S. Park,et al.  Tissue-specific recognition of mouse CD1 molecules. , 1998, Journal of immunology.

[30]  U. Kavita,et al.  CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. , 1998, Journal of immunology.

[31]  D. Carson,et al.  Induction of an Antigen-specific, CD1-restricted Cytotoxic T Lymphocyte Response In vivo , 1998, The Journal of experimental medicine.

[32]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[33]  K. Heeg,et al.  Immunostimulatory DNA: Sequence‐dependent production of potentially harmful or useful cytokines , 1997, European journal of immunology.

[34]  Hiroshi Sato,et al.  Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .

[35]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[36]  G. Weiner,et al.  Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Blank,et al.  CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants , 1997, European journal of immunology.

[38]  A. Krieg,et al.  Bacterial DNA-Induced NK Cell IFN-γ Production Is Dependent on Macrophage Secretion of IL-12 , 1997 .

[39]  M. Kronenberg,et al.  Mouse CD1 is mainly expressed on hemopoietic-derived cells. , 1997, Journal of immunology.

[40]  D. Richman,et al.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.

[41]  S. Balk,et al.  Requirements for CD1d Recognition by Human Invariant Vα24+ CD4−CD8− T Cells , 1997, The Journal of experimental medicine.

[42]  G. Weiner,et al.  Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. , 1997, Blood.

[43]  Chyung-Ru Wang,et al.  Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. , 1997, Immunity.

[44]  Seokmann Hong,et al.  CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. , 1997, Immunity.

[45]  I. Goldschneider,et al.  Direct thymic involvement in anterior chamber-associated immune deviation: evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice. , 1997, Journal of immunology.

[46]  M. Kaplan,et al.  Immunoglobulin E Production in the Absence of Interleukin-4-Secreting CD1-Dependent Cells , 1997, Science.

[47]  S. Park,et al.  Mouse CD1-specific NK1 T cells: development, specificity, and function. , 1997, Annual review of immunology.

[48]  T. Tokuhisa,et al.  Essential requirement of an invariant V alpha 14 T cell antigen receptor expression in the development of natural killer T cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Zlotnik,et al.  Mouse NK1.1+ T cells: a new family of T cells. , 1996, Immunology today.

[50]  A. Bendelac Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes , 1995, The Journal of experimental medicine.

[51]  C. Benoist,et al.  CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice , 1995, The Journal of experimental medicine.

[52]  H. Macdonald NK1.1+ T cell receptor-alpha/beta+ cells: new clues to their origin, specificity, and function , 1995, The Journal of experimental medicine.

[53]  R. Locksley,et al.  Natural T cells. Cells that co-express NKRP-1 and TCR. , 1995, Journal of immunology.

[54]  J. Yewdell,et al.  CD1 recognition by mouse NK1+ T lymphocytes. , 1995, Science.

[55]  K. Takeda,et al.  Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. , 1995, Journal of immunology.

[56]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[57]  A. Bendelac Mouse NK1+ T cells. , 1995, Current opinion in immunology.

[58]  Y. Koezuka,et al.  KRN7000, a novel immunomodulator, and its antitumor activities. , 1995, Oncology research.

[59]  A. Lanzavecchia,et al.  An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells , 1994, The Journal of experimental medicine.

[60]  O. Lantz,et al.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans , 1994, The Journal of experimental medicine.

[61]  W. Paul,et al.  CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3 , 1994, The Journal of experimental medicine.

[62]  S. Balk,et al.  Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain , 1993, The Journal of experimental medicine.

[63]  F. Sallusto,et al.  In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4-8- subset , 1993, The Journal of experimental medicine.

[64]  F. Sallusto,et al.  In Vivo Persistence of Expanded Clones Specific for Bacterial Antigens within the Human T Cell Receptor ce//~ CD4-8- Subset By Paolo Dellabona,* Giulia Casorati,* Brigitte Friedli, , 1993 .

[65]  E. Kuramoto,et al.  Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. , 1992, Journal of immunology.